Skip to main content
Premium Trial:

Request an Annual Quote

AMDL Inks Sub-licensing Deal for HPV Kit in Asian Markets

NEW YORK (GenomeWeb News) – The molecular diagnostics company AMDL said today that it has licensed a human papillomavirus diagnostic genotyping test from MyGene International for use in Asia.
 
Under the exclusive sublicense agreement, AMDL will use MyGene’s HPV Chip Kit patents to make, market, sell, and distribute the MyGene HPV Test Kit in China, Taiwan, Singapore, Malaysia, Thailand, Cambodia, and Vietnam.
 
AMDL is based in Tustin, Calif., but also has operations in three cities in China. The company’s Chinese branch is run through its subsidiary, Jade Pharmaceutical International.
 
AMDL said an “extremely conservative” estimate for a market for HPV testing in China could be around $50 million. The company also said that there are around 330 million women infected with HPV in the world, and that 70 percent of the existing infections are in Asian populations.
 
Financial terms of the agreement were not released.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.